9 Meters Biopharma (NMTR) News Today Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Energy firms likely to miss smart meter deadline, warns Which?December 14, 2023 | bbc.comDeal reached to sell some assets of bankrupt Raleigh firmNovember 8, 2023 | bizjournals.com9 Meters Biopharma, Inc. (NMTRQ)November 7, 2023 | finance.yahoo.com9 Meters Biopharma Inc (NMTRQ)October 17, 2023 | investing.com9 Meters Biopharma (OTC: NMTR.Q)August 16, 2023 | fool.comRaleigh firm joins worrying trend of bankruptcies for drugmakersJuly 18, 2023 | bizjournals.comDrug developer 9 Meters Biopharma files for bankruptcy protectionJuly 18, 2023 | reuters.comWhy Are 9 Meters Biopharma Shares Nosediving Today?July 18, 2023 | finance.yahoo.comTemperato resigns as CEO of Raleigh drugmakerMay 30, 2023 | bizjournals.com9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel SyndromeMay 30, 2023 | finance.yahoo.com9 Meters Biopharma (NASDAQ: NMTR)May 28, 2023 | fool.comNMTR - 9 Meters Biopharma, Inc.May 25, 2023 | uk.finance.yahoo.comCitigroup Maintains 9 Meters Biopharma (NMTR) Neutral RecommendationMay 19, 2023 | msn.com9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023May 15, 2023 | finance.yahoo.com9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for ObesityApril 5, 2023 | finance.yahoo.comWhy this Raleigh pharma just cut half its workforceMarch 30, 2023 | bizjournals.com9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2022March 28, 2023 | finance.yahoo.comNMTR 9 Meters Biopharma, Inc.March 25, 2023 | seekingalpha.com9 Meters Biopharma Stock (NASDAQ:NMTR), Guidance and ForecastMarch 22, 2023 | benzinga.comRaleigh pharma raises $5M as phase 3 study beginsMarch 16, 2023 | bizjournals.com9 Meters Biopharma Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesMarch 15, 2023 | finance.yahoo.com9 Meters Biopharma Announces $5 Million Registered Direct Offering Priced at-the-Market Under Nasdaq RulesMarch 14, 2023 | finance.yahoo.com9 Meters Biopharma to Present at the Oppenheimer 33rd Annual Healthcare ConferenceMarch 7, 2023 | finance.yahoo.comSuppliers told to remove prepayment meters that were wrongly force-fittedFebruary 23, 2023 | theguardian.com9 Meters Biopharma to Present at the 2023 BIO CEO & Investor ConferenceJanuary 31, 2023 | finance.yahoo.comLabour calls for halt to ‘shameful’ forced installation of prepayment metersJanuary 17, 2023 | theguardian.comMPs warn over forced prepayment meters as cold weather returnsJanuary 15, 2023 | theguardian.comEnergy bills: 'I was forced onto a prepayment meter'January 14, 2023 | news.yahoo.comMillions of families forced to have prepayment gas and electric metersJanuary 14, 2023 | thetimes.co.uk9 Meters Biopharma Announces Phase 3 Study of Vurolenatide in Short Bowel SyndromeNovember 29, 2022 | finance.yahoo.com9 Meters Biopharma Announces Continued Immuno-Oncology Collaboration with Gustave RoussyNovember 14, 2022 | finance.yahoo.com9 Meters Biopharma Provides Business Update and Reports Financial Results for Third Quarter 2022November 8, 2022 | finance.yahoo.com9 Meters Biopharma Presents Preclinical Data on Glucose-Dependent Insulinotropic Polypeptide (GIP) Monoclonal Antibodies for Obesity at the American College of Gastroenterology 2022 Annual Scientific MeetingOctober 24, 2022 | finance.yahoo.com9 Meters Biopharma triggers reverse stock split to maintain Nasdaq listingOctober 18, 2022 | bizjournals.com9 Meters Biopharma to Present at the American College of Gastroenterology (ACG) 2022 Annual Scientific MeetingOctober 18, 2022 | finance.yahoo.com9 Meters Biopharma Announces 1-for-20 Reverse Stock SplitOctober 17, 2022 | finance.yahoo.com9 Meters Biopharma gains after mid-stage data for short bowel syndrome drugSeptember 27, 2022 | seekingalpha.com9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel SyndromeSeptember 26, 2022 | finance.yahoo.com9 Meters Biopharma to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceSeptember 6, 2022 | finance.yahoo.com9 Meters Biopharma to Participate at the 44th European Society for Clinical Nutrition and Metabolism (ESPEN) CongressSeptember 1, 2022 | finance.yahoo.com9 Meters Biopharma to Participate in the Citi 17th Annual BioPharma ConferenceAugust 31, 2022 | finance.yahoo.com9 Meters Biopharma, Inc. (NMTR)August 13, 2022 | uk.finance.yahoo.com9 Meters Biopharma to Participate in the William Blair Biotech Focus Conference 2022July 6, 2022 | finance.yahoo.comRaleigh drugmaker shifts focus after trial setbackJuly 5, 2022 | bizjournals.com9 Meters stock falls despite drug showing promise in short bowel syndrome trialJune 30, 2022 | seekingalpha.com9 Meters gets $70M debt facility for phase 3 development of short bowel syndrome drugJune 30, 2022 | seekingalpha.com9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel SyndromeJune 30, 2022 | finance.yahoo.com9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel SyndromeJune 30, 2022 | finance.yahoo.comRaleigh pharma sees stock tumble after stopping trial. Now what?June 22, 2022 | finance.yahoo.com9 Meters stock slumps 54% as phase 3 Celiac disease trial of larazotide gets axedJune 21, 2022 | seekingalpha.com Get 9 Meters Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter. Email Address This company will win the AI race (Ad)Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. NMTR Media Mentions By Week NMTR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NMTR News Sentiment▼0.000.87▲Average Medical News Sentiment NMTR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NMTR Articles This Week▼00▲NMTR Articles Average Week Get 9 Meters Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CHRO News OGEN News CPHI News APM News ATXI News SNOA News GENE News LIPO News KTTA News REVB News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NMTR) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 9 Meters Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 9 Meters Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
